Amy S. Clark, MD, MSCE

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-154
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-7096
Fax: 215-615-3349
Education:
BS (Biology)
Haverford College, 1999.
MD (Medicine)
Milton S. Hershey Penn State College of Medicine, 2006.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2012.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

I am a medical oncologist who specializes in breast cancer. I only see breast cancer patients in the outpatient setting, but treat patients will all cancers when working in the hospital.

Description of Research Expertise

My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.

Selected Publications

Esserman L, Yeee D, DeMichele A, Yau C, Issacs C, Symmans WF, Albain K, Chen Yunn-yi, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocoo A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal I, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Yang S, Adams A, Chein AJ, Forero-Torres T, Stringer-Reasor E, Wallace AM, Pusztai L, Boughry JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Visvcusi RK, Euhus DM, Edison KK, Chi AY, Kemmer K, Wood WC, Park JW, Liu MC, Olopade O, Layland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, van 't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paolini M, Clennel JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Beery DA: Disease-free survival correlates with pathologic complete response in the adaptively randomized I-SPY2 trial of stage 2/3 breast cancer. The Lancet 2020 Notes: In Press.

McDonald E, Doot RK, Carlin SD, Pantel A, Shah PD, Clark AS, Desai H, Kelly G, Young AJ, Pryma DA, Farewell MD, Nayak A, Lee H, Schubert EK, Makvandi M, Xiober A, Tchou J, DeMichele A, Feldman M, Domchek SM, Mach RH, Maxwell KN, Manoff: PARP Imaging in Breast Bancer. JAMA Oncology 2020 Notes: In Press.

Clark AS,: Refining the indications for neoadjuvant chemotherapy (NAC) for patients with HER2+ breast cancer – a single institution experience. Journal of Surgical Oncology 2020.

Nivar I, Kaufmann T, Bayne L, Goodspeed B, Chodosh L, Feldman M, Wileyto P, Clark AS, DeMichele A: Patient attitudes, experience and results of screening for minimal residual disease (MRD) for therapeutic intervention. San Antonio Texas Breast Cancer Symposium® Dec 2019 Notes: Poster Presentation.

Nivar I, Kaufmann T, Bayne L, Goodspeed B, Chodosh L, Feldman M, Wileyto P, Clark A, DeMichele A: Patient attitudes, experience and results of screening for minimal residual disease (MRD) for therapeutic intervention. San Antonio Texas Breast Cancer Symposium® Dec 2019.

Yau C, DeMichele A, Symmans W, Pusztai L, Yee D, CLark AS, Hatzis C, Matthews JB, Carter J, Chen Y, Cole K, Khazai L, Klein M, Kokh D, Krings G, Sahoo S, Albian KS, Chien A, Edminston KK, Elias AD, Ellis ED, Euhus DM, Han HS, Issacs C, Kahn OJ, Lang JE, Lu J, Meisel JL, Mitri Z, Nanda R, Northfelt DW, Sanft T, Stringer-Reasor E, Viscusi RK, Wallace AM, Yung R, Hylton NM, Boughey JC, Melisko ME, Perlmutter J, Rugo HS, Schwab R, Van't Veer LJ, Berry DA, Esserman LJ: Site of recurrence after neoadjuvant therapy: clues to biology and impact on endpoints. San Antonio Texas Breast Cancer Symposium® Dec 2019.

Bardia, A., Hurvitz, S., DeMichele, A., Clark, A.S., Zelnak, A., Yardley, D., Karuturi, M., Sanft, T., Blau, S., Hart, L., Mia, C., Caria, N., Purkayastha, D., Mistry, A., Moulder, S.: Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): efficacy, safety, and biomarker results. ASCO 2019 – TRINITI-1, Chicago Illinois Jun 2019.

Dreyfuss AD, Barsky AR, Taunk NK, Clark AS, Freedman GM: The Efficacy and Safety of Hypofractionated Radiotherapy with Concurrent Anti-HER-2 Therapy Following Breast-Conserving Therapy for Breast Cancer. The Breast Journal June 2019.

Mankoff DA, Clark AS: PET oestrogen receptor imaging: ready for the clinic? The Lancet Oncology Mar 2019.

Elmi, A., Makvandi, M., Weng, C.C., Hou, C., Clark, AS., Mach, R.H., Mankoff, D.A.: Cell-proliferation imaging for monitoring response to CDK4/6 inhibition combined with endocrine-therapy in breast cancer: Comparison of [18F]FLT and [18F]ISO-1 PET/CT. Clin Cancer Res Jan 2019.

back to top
Last updated: 12/20/2019
The Trustees of the University of Pennsylvania